Harpoon Therapeutics, Inc. announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of biopharma business development, finance, and mergers and acquisitions (M&A) transaction experience to Harpoon. Mr. Wang most recently served as Vice President of Business Development at Hummingbird Bioscience where he was responsible for the company?s end-to-end business development activities.

Prior to Hummingbird, Mr. Wang was Director of Business Development at Amgen, where he played a major role in the Teneobio and Five Prime Therapeutics acquisitions, the oncology collaboration with BeiGene, and many clinical collaborations to advance Amgen?s oncology pipeline. Prior to Amgen, Mr. Wang was an M&A consultant at Deloitte, advising on numerous transactions in the healthcare and tech sectors in China. He received his M.S. in Biotechnology from Johns Hopkins University, MBA from Duke University, and B.S. from Tsinghua University.